ijms-logo

Journal Browser

Journal Browser

Soft Tissue Mineralization: Mechanisms, Diseases and Prevention

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 3621

Special Issue Editor


E-Mail Website
Guest Editor
Centre de Recherche des Cordeliers, INSERM, UMRS-1138, Université de Paris, F-75006 Paris, France
Interests: rare disease; mouse model; biomarker; kidney

Special Issue Information

Dear Colleagues,

Physiological extracellular matrix mineralization concerns bone, teeth and otoconia. Ectopic calcification of soft tissues and vasculature is, on the other hand, associated with aging, rare genetic disorders, common metabolic diseases or results from the use of pharmaceuticals. Many aspects of pathological calcification are an active area of research including the type of cells involved, the calcification timeline, the cellular pathways, the interactions between the mineral and the surrounding tissue and the relationships of these factors with disease progression.

Several environmental and genetic factors contributing to the calcification have been identified and studies in mouse knock out models have shown that ectopic calcification is under the control of local and systemic calcification inhibitors.

The current view is that the regulation of ectopic/pathological calcification is a multifactorial process that includes phenotypic cell transition to an osteo-chondroblastic phenotype and an imbalance in the regulatory mechanisms that induce or prevent calcification.

At present very limited pharmaceutical strategies exist to inhibit soft tissue calcification. The development of effective therapies and biomarkers to predict the progression of the calcification event are thus main challenges. Knowledge coming from the deep characterization of the molecular pathways involved in human pathologies as well as the development of new animal models will be very helpful.

We invite investigators to contribute original research and review articles that will highlight the pathogenetic mechanisms of the calcification diseases, propose potential therapeutic and preventive targets and identify biomarkers to predict the development of the disease.

Dr. Renata Kozyraki
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • calcification
  • pathologic
  • chronic disease
  • rare disease
  • mouse model
  • biomarker
  • treatment

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1959 KiB  
Article
A Proteomic Screen to Unravel the Molecular Pathways Associated with Warfarin-Induced or TNAP-Inhibited Arterial Calcification in Rats
by Britt Opdebeeck, Ellen Neven, Stuart Maudsley, Hanne Leysen, Deborah Walter, Hilde Geryl, Patrick C. D’Haese and Anja Verhulst
Int. J. Mol. Sci. 2023, 24(4), 3657; https://doi.org/10.3390/ijms24043657 - 11 Feb 2023
Cited by 2 | Viewed by 1295
Abstract
Arterial media calcification refers to the pathological deposition of calcium phosphate crystals in the arterial wall. This pathology is a common and life-threatening complication in chronic kidney disease, diabetes and osteoporosis patients. Recently, we reported that the use of a TNAP inhibitor, SBI-425, [...] Read more.
Arterial media calcification refers to the pathological deposition of calcium phosphate crystals in the arterial wall. This pathology is a common and life-threatening complication in chronic kidney disease, diabetes and osteoporosis patients. Recently, we reported that the use of a TNAP inhibitor, SBI-425, attenuated arterial media calcification in a warfarin rat model. Employing a high-dimensionality unbiased proteomic approach, we also investigated the molecular signaling events associated with blocking arterial calcification through SBI-425 dosing. The remedial actions of SBI-425 were strongly associated with (i) a significant downregulation of inflammatory (acute phase response signaling) and steroid/glucose nuclear receptor signaling (LXR/RXR signaling) pathways and (ii) an upregulation of mitochondrial metabolic pathways (TCA cycle II and Fatty Acid β-oxidation I). Interestingly, we previously demonstrated that uremic toxin-induced arterial calcification contributes to the activation of the acute phase response signaling pathway. Therefore, both studies suggest a strong link between acute phase response signaling and arterial calcification across different conditions. The identification of therapeutic targets in these molecular signaling pathways may pave the way to novel therapies against the development of arterial media calcification. Full article
(This article belongs to the Special Issue Soft Tissue Mineralization: Mechanisms, Diseases and Prevention)
Show Figures

Figure 1

10 pages, 3060 KiB  
Communication
Minocycline Counteracts Ectopic Calcification in a Murine Model of Pseudoxanthoma Elasticum: A Proof-of-Concept Study
by Elise Bouderlique, Lukas Nollet, Emmanuel Letavernier and Olivier M. Vanakker
Int. J. Mol. Sci. 2022, 23(3), 1838; https://doi.org/10.3390/ijms23031838 - 6 Feb 2022
Cited by 6 | Viewed by 1771
Abstract
Pseudoxanthoma elasticum (PXE) is an intractable Mendelian disease characterized by ectopic calcification in skin, eyes and blood vessels. Recently, increased activation of the DNA damage response (DDR) was shown to be involved in PXE pathogenesis, while the DDR/PARP1 inhibitor minocycline was found to [...] Read more.
Pseudoxanthoma elasticum (PXE) is an intractable Mendelian disease characterized by ectopic calcification in skin, eyes and blood vessels. Recently, increased activation of the DNA damage response (DDR) was shown to be involved in PXE pathogenesis, while the DDR/PARP1 inhibitor minocycline was found to attenuate aberrant mineralization in PXE cells and zebrafish. In this proof-of-concept study, we evaluated the anticalcifying properties of minocycline in Abcc6−/− mice, an established mammalian PXE model. Abcc6−/− mice received oral minocycline supplementation (40 mg/kg/day) from 12 to 36 weeks of age and were compared to untreated Abcc6−/− and Abcc6+/+ siblings. Ectopic calcification was evaluated using X-ray microtomography with three-dimensional reconstruction of calcium deposits in muzzle skin and Yasue’s calcium staining. Immunohistochemistry for the key DDR marker H2AX was also performed. Following minocycline treatment, ectopic calcification in Abcc6−/− mice was significantly reduced (−43.4%, p < 0.0001) compared to untreated Abcc6−/− littermates. H2AX immunostaining revealed activation of the DDR at sites of aberrant mineralization in untreated Abcc6−/− animals. In conclusion, we validated the anticalcifying effect of minocycline in Abcc6−/− mice for the first time. Considering its favorable safety profile in humans and low cost as a generic drug, minocycline may be a promising therapeutic compound for PXE patients. Full article
(This article belongs to the Special Issue Soft Tissue Mineralization: Mechanisms, Diseases and Prevention)
Show Figures

Figure 1

Back to TopTop